# US 2021/0275627 A1 · Methods and compositions for the treatment of radiation-related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275627 A1
- Document ID: US20210275627A1
- Status: Published application
- Kind: A1
- Application number: 17/090,237
- Filed: 2020-11-05
- Published: 2021-09-09
- Earliest claimed: 2014-10-16
- Assignees: Cleveland BioLabs, Inc.
- Applicants: Cleveland BioLabs, Inc.
- Inventors: Vadim KRIVOKRYSENKO; Elena FEINSTEIN
- Web page: https://patentgrep.com/patent/US20210275627A1

## CPC

- A61K 38/164: {from bacteria}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/68: Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 39/00: General protective or antinoxious agents
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61N 5/00: Radiation therapy (ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00)
- C07K 14/195: from bacteria
- C07K 14/255: Salmonella (G)
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention relates, in part, to methods and compositions that are useful for the treatment and/or prevention of various disorders, including radiation-related disorders, such as acute radiation syndrome.

## Claims

### Claim at position 1

-32. (canceled)

### Claim 33

A method of preventing gastrointestinal damage following exposure to radiation in a human patient, the method comprising administering to the human patient not more than a single dose of an effective amount of a composition comprising entolimod, wherein the effective amount is about 0.4 to about 0.6 μg/kg, and wherein the entolimod comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 34 (depends on 33)

The method of claim 33, wherein the exposure to radiation occurs as a result of a radiation disaster.

### Claim 35 (depends on 33)

The method of claim 33, wherein the irradiation is a high dose of radiation of at least 2 Gy.

### Claim 36 (depends on 33)

The method of claim 33, wherein the high dose of radiation is sufficient for a classification of Unit Radiation Exposure Status of RES 3.

### Claim 37 (depends on 33)

The method of claim 33, wherein the human patient is administered entolimod within about 48 hours of being exposed to radiation.

### Claim 38 (depends on 33)

The method of claim 33, wherein the human patient is administered entolimod within one or more of the triage, emergency care, and definitive care stages of radiation exposure.

### Claim 39 (depends on 33)

The method of claim 33, wherein entolimod is administered parenterally or orally.

### Claim 40 (depends on 33)

The method of claim 33, wherein entolimod is administered by a single intramuscular injection.

### Claim 41 (depends on 33)

The method of claim 33, wherein entolimod is administered by controlled-release or sustained-release.

### Claim 42 (depends on 33)

The method of claim 33, wherein the human patient presents a lymphocyte count reduction of about 50% within about 24 to about 48 hours of being exposed to radiation.

### Claim 43 (depends on 33)

The method of claim 33, wherein the human patient's lymphocyte count is less than about 1000/μL.

### Claim 44 (depends on 33)

The method of claim 33, wherein the treatment with entolimod is used as an adjuvant or neoadjuvant to one or more of blood products, colony stimulating factors, cytokines and/or growth factors, antibiotics, diluting and/or blocking agents, mobilizing or chelating agents, stem cell transplants, antioxidants or free radicals, and radioprotectants.

### Claim 45 (depends on 33)

The method of claim 33, wherein entolimod induces expression of NF-κB through toll-like receptor (TLR)-mediated activation.
